| Title: |
PS1245 NIVOLUMAB FOR RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: LONG TERM RESULTS OF MULTI‐CENTER EXPERIENCE IN TURKEY |
| Authors: |
Ferhanoglu, B.; Ozbalak, M.; Bekoz, H.; Karadurmus, N.; Paydas, S.; Turker, A.; Toptas, T.; Tuglular, T. Firatli; Sonmez, M.; Gulbas, Z.; Demir, N.; Kaynar, L.; Yildirim, R.; Karadogan, I.; Arat, M.; Tanrikulu, F. Pepedil; Ozkocaman, V.; Abali, H.; Turgut, M.; Yuksel, M. Kurt; Ozcan, M.; Hacioglu, S. Kabukcu; Barista, I.; Demirkaya, M.; Atilla, F.D.; Toprak, S.K.; Yilmaz, M. |
| Source: |
HemaSphere ; volume 3, issue S1, page 567-568 ; ISSN 2572-9241 2572-9241 |
| Publisher Information: |
Wiley |
| Publication Year: |
2019 |
| Collection: |
Wiley Online Library (Open Access Articles via Crossref) |
| Description: |
Background: The programmed death‐1 (PD‐1) inhibitors have been approved by FDA for patients who relapse following autologous stem cell transplantation and brentuximab vedotin (BV) therapy. Aims: We aimed to present long‐term results of our previously published retrospective multicenter study about the efficacy and safety of nivolumab in the “real‐life” setting in Turkey (Bekoz et al. Ann Oncol 2017) Methods: 23 centers from Turkey participated in this study. Eligible patients were required those treated with at least 1 course of nivolumab and with available radiological response evaluation. Patients received nivolumab via a named‐patient program. Nivolumab was adminstered at standard dose and schedule until death of any cause, unacceptable toxicity, withdrawal of consent, or primary physician's decision. The study was approved by the local ethical commitee. The primary endpoint was the overall response rate (ORR); secondary endpoints were overall survival (OS), PFS, and safety. The response was assessed by positron‐emission tomography/computed tomography or CT. Response evaluation was performed according to the Lugano Classification and its update regarding immunomodulatory therapy. Results: Between 06/2015–11/2016, 86 patients from 23 centers were retrospectively analyzed. Although initial response evaluation was complete for seven patients, we could not reach their long‐term medical records and we included them in our analysis. Median follow‐up was 27.5 months, median age was 29 (18–75) and patients had a median 5 (2–11) previous lines of therapy. 59 patients (69%) had been treated by stem cell transplantation (SCT) and 46 (77%) patients had been treated by BV. The best overall response rate was 70% (CR in 34% and PR in 36%). The median PFS was 33.5 months and, the median OS was not reached. The 24‐month PFS and OS rates were 60% (95% CI 0.48–069) and 82% (95% CI 0.72–0.87), respectively. 79% and 53% of patients who achieved CR and PR continue their response at a median follow‐up of 30 and 29 months, ... |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1097/01.hs9.0000563260.18006.d6 |
| DOI: |
10.1097/01.HS9.0000563260.18006.d6 |
| Availability: |
http://dx.doi.org/10.1097/01.hs9.0000563260.18006.d6; https://onlinelibrary.wiley.com/doi/pdf/10.1097/01.HS9.0000563260.18006.d6 |
| Rights: |
http://onlinelibrary.wiley.com/termsAndConditions#vor |
| Accession Number: |
edsbas.36EA39DF |
| Database: |
BASE |